Seattle Allergy and Asthma Research Institute   Report issue

Academic/Hospital
Founded: Seattle WA United States (1964)

Organization Overview

First Clinical Trial
2016
NCT02814630
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Other Trials (1)

omalizumab (xolair) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1